

Cyclosporine consensus conference: With emphasis on

Journal of the American Academy of Dermatology  
39, 464-475

DOI: 10.1016/s0190-9622(98)70325-1

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cyclosporine-associated lymphoma. Journal of the American Academy of Dermatology, 1999, 40, 1015-1016.	0.6	8
3	Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results. Journal of the American Academy of Dermatology, 1999, 41, S25-S28.	0.6	110
4	Immunosuppressant-Induced Nephropathy. Drug Safety, 1999, 21, 471-488.	1.4	96
5	Current Consensus and Update on Psoriasis Therapy: A Perspective from the U.S.. Journal of Dermatology, 1999, 26, 723-733.	0.6	68
6	Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment. British Journal of Dermatology, 2000, 143, 950-956.	1.4	21
7	Concerns over the Present FDA Guidelines for the use of Cyclosporine in Psoriasis. Psoriasis Forum, 2000, 6a, 4-5.	0.1	0
8	Combination Systemic Therapy in the Treatment of Psoriasis. Psoriasis Forum, 2000, 6a, 1-4.	0.1	0
9	Pilomatrix dysplasia in an immunosuppressed patient. Journal of the American Academy of Dermatology, 2000, 43, 118-122.	0.6	47
10	Cyclosporine: An overview. Current Problems in Dermatology, 2000, 12, 268-269.	0.1	1
11	Immunosuppressant and cytotoxic drugs: unapproved uses or indications. Clinics in Dermatology, 2000, 18, 95-101.	0.8	7
12	Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, The, 2000, 356, 385-390.	6.3	1,387
13	NEW AND EMERGING THERAPIES IN THE TREATMENT OF BLISTERING DISEASES. Dermatologic Clinics, 2000, 18, 127-137.	1.0	42
14	ESTABLISHING A PRACTICAL AND EFFECTIVE PSORIASIS TREATMENT CENTER. Dermatologic Clinics, 2000, 18, 349-357.	1.0	1
15	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. Journal of the American Academy of Dermatology, 2001, 44, 643-651.	0.6	142
16	Uses and complications of isotretinoin therapy. Journal of the American Academy of Dermatology, 2001, 45, S150-S157.	0.6	183
17	Treatment of psoriasis. Part 2. Systemic therapies. Journal of the American Academy of Dermatology, 2001, 45, 649-664.	0.6	184
18	NEW IMMUNOMODULATING DRUGS IN AUTOIMMUNE BLISTERING DISEASES. Dermatologic Clinics, 2001, 19, 637-648.	1.0	26
19	CYCLOSPORINE AND TACROLIMUS IN DERMATOLOGY. Dermatologic Clinics, 2001, 19, 119-137.	1.0	44

#	ARTICLE	IF	CITATIONS
20	Calcipotriol Ointment. American Journal of Clinical Dermatology, 2001, 2, 95-120.	3.3	85
21	Management of Psoriasis Vulgaris with Methotrexate 0.25% in a Hydrophilic Gel: A Placebo-Controlled, Double-Blind Study. Journal of Cutaneous Medicine and Surgery, 2001, 5, 299-302.	0.6	14
22	Management of Psoriasis Vulgaris with Methotrexate 0.25% In a Hydrophilic Gel: A Placebo-Controlled, Double-Blind Study. Journal of Cutaneous Medicine and Surgery, 2001, 5, 299-302.	0.6	28
23	Psoriasis: the future. British Journal of Dermatology, 2001, 144, 37-43.	1.4	41
24	Therapeutic concepts in clinical dermatology: cyclosporine A in immunomediated and other dermatoses. International Journal of Dermatology, 2001, 40, 551-561.	0.5	10
25	Psoriasis: the future. British Journal of Dermatology, 2001, 144, 37-43.	1.4	32
26	New Developments in the Treatment of Psoriasis. Archives of Dermatology, 2002, 138, 686-8.	1.7	43
27	Psoriasis and Pregnancy. Journal of Cutaneous Medicine and Surgery, 2002, 6, 561-570.	0.6	56
28	Practical Management of Psoriasis in the Elderly. Drugs and Aging, 2002, 19, 847-863.	1.3	54
29	Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. Journal of the American Academy of Dermatology, 2002, 46, 242-250.	0.6	25
30	Psoriasis and Pregnancy. Journal of Cutaneous Medicine and Surgery, 2002, 6, 561-570.	0.6	94
31	Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well Tolerated. Journal of Investigative Dermatology, 2002, 119, 876-887.	0.3	109
32	Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. British Journal of Dermatology, 2002, 147, 122-129.	1.4	36
33	Cyclosporin: applications in small animal dermatology. Veterinary Dermatology, 2003, 14, 1-9.	0.4	55
34	Lupus miliaris disseminatus faciei and its debated link to tuberculosis. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 97-97.	1.3	14
35	A case of important nodular fasciitis of the leg. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 109-111.	1.3	1
36	Homage to Reverdin: pinch grafting. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 111-113.	1.3	5
37	Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 113-114.	1.3	14

#	ARTICLE	IF	CITATIONS
38	Cutaneous lichen planus and squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 98-100.	1.3	24
39	Tuberous sclerosis with unusual giant unguial fibromas. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 100-101.	1.3	8
40	Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 101-103.	1.3	54
41	Pemphigus vulgaris lesion on a melanocytic naevus. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 103-104.	1.3	4
42	Large B-cell lymphoma of the skin arising on a background of polyclonal B-cell hyperplasia. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 104-105.	1.3	1
43	Safety of cyclosporin A in the treatment of dermatological diseases. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 105-107.	1.3	4
44	Hyalinosis cutis et mucosae: excessively secreted basal lamina by pericytes and myofibroblasts and its conversion to hyalin. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 107-108.	1.3	5
45	Gynaecomastia following treatment by fluoxetine. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 109-109.	1.3	15
46	Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 114-116.	1.3	9
47	CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. British Journal of Dermatology, 2003, 149, 170-173.	1.4	108
48	Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nature Medicine, 2003, 9, 40-46.	15.2	412
49	Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal of Dermatological Treatment, 2003, 14, 7-16.	1.1	6
50	Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. Veterinary Record, 2003, 152, 739-748.	0.2	55
51	Current systemic therapies for psoriasis: where are we now?. Journal of the American Academy of Dermatology, 2003, 49, 66-77.	0.6	57
52	Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis. New England Journal of Medicine, 2003, 349, 658-665.	13.9	446
53	Short course of oral cyclosporine in lichen planopilaris. Journal of the American Academy of Dermatology, 2003, 49, 667-671.	0.6	84
54	Prevalence of Joint Disease in Patients with Psoriasis. American Journal of Clinical Dermatology, 2003, 4, 441-447.	3.3	240
55	Optimal Treatment of Pyoderma Gangrenosum. American Journal of Clinical Dermatology, 2003, 4, 597-608.	3.3	48

#	ARTICLE	IF	CITATIONS
56	Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opinion on Pharmacotherapy, 2003, 4, 1525-1533.	0.9	58
57	Efficacy and Safety of Cyclosporine <i>versus</i> Methotrexate in Severe Psoriasis: A Study from North India. Journal of Dermatology, 2003, 30, 458-463.	0.6	35
58	Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine. Dermatology, 2003, 206, 330-333.	0.9	40
59	Beware of Package Inserts. Psoriasis Forum, 2003, 9a, 10-11.	0.1	0
60	Advances in Immunosuppressive Drug Therapy for Use in Autoimmune Disease and Systemic Vasculitis. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 581-594.	0.8	13
61	T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva®, c): Mechanisms of Action. Dermatology, 2004, 208, 297-306.	0.9	112
62	Biologics in combination with nonbiologics: efficacy and safety. Dermatologic Therapy, 2004, 17, 432-440.	0.8	32
63	Cyclosporine in severe psoriasis: an Indian experience. International Journal of Dermatology, 2004, 43, 623-624.	0.5	1
64	Biological therapies in the systemic management of psoriasis: International Consensus Conference. British Journal of Dermatology, 2004, 151, 3-17.	1.4	164
65	Cyclosporin in psoriasis: how?. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 250-253.	1.3	1
67	Therapeutic potential of macrolide immunosuppressants in dermatology. Expert Opinion on Investigational Drugs, 2004, 13, 125-137.	1.9	4
68	Novel biologic therapies for psoriasis. Expert Opinion on Biological Therapy, 2004, 4, 975-987.	1.4	19
69	Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology, 2004, 50, 416-430.	0.6	178
71	Methotrexate and psoriasis in the era of new biologic agents. Journal of the American Academy of Dermatology, 2004, 50, 301-309.	0.6	56
73	The effects of oral cyclosporine in plaque-type psoriasis: the experience of Andreas Sygros Hospital. Therapy: Open Access in Clinical Medicine, 2004, 1, 217-221.	0.2	0
74	Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II. Journal of Cutaneous Medicine and Surgery, 2005, 9, 313-323.	0.6	4
75	Novel gels and their dispersionsâ€”oral drug delivery systems for ciclosporin. International Journal of Pharmaceutics, 2005, 300, 113-124.	2.6	32
76	Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. International Journal of Clinical Practice, 2005, 59, 1260-1267.	0.8	37

#	ARTICLE	IF	CITATIONS
77	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. <i>British Journal of Dermatology</i> , 2005, 152, 597-615.	1.4	165
78	The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 34, 819-836.	1.6	191
79	Post-transplant cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 137-145.	2.0	53
80	Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 313-323.	0.6	24
81	Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 33-55.	2.2	10
82	Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study. <i>Journal of Dermatological Treatment</i> , 2005, 16, 238-241.	1.1	12
83	Psoriasis treatment: traditional therapy. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, ii83-ii86.	0.5	86
84	The Use of Systemic Immune Moderators in Dermatology: An Update. <i>Dermatologic Clinics</i> , 2005, 23, 259-300.	1.0	50
85	Psoriasis: a fresh look. <i>Clinics in Dermatology</i> , 2005, 23, 491-502.	0.8	28
86	Incidence of infection during efalizumab therapy for psoriasis: Analysis of the clinical trial experience. <i>Clinical Therapeutics</i> , 2005, 27, 1317-1328.	1.1	55
87	An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. <i>Clinical Therapeutics</i> , 2005, 27, 1912-1921.	1.1	67
88	A Treatment Strategy for Psoriasis: Transitioning From Systemic Therapy to Biologic Agents. <i>Skinmed</i> , 2006, 5, 285-290.	0.0	18
89	A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 472-478.	0.6	54
90	Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S135-S138.	0.6	24
91	Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S154-S163.	0.6	78
92	The Medical Treatment of Cicatricial Alopecia. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2006, 25, 56-59.	1.6	43
93	Treatment of Psoriasis. <i>Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association</i> , 2006, 49, 150.	0.1	0
95	Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 639-650.	1.3	35

#	ARTICLE	IF	CITATIONS
96	Cyclosporin A treatment in severe childhood psoriasis. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 651-656.	1.3	60
97	TWO-STAGE THERAPY FOR CHILDHOOD GENERALIZED PUSTULAR PSORIASIS: LOW-DOSE CYCLOSPORIN FOR INDUCTION AND MAINTENANCE WITH ACITRETIN/NARROWBAND ULTRAVIOLET B PHOTOTHERAPY. Pediatric Dermatology, 2006, 23, 306-308.	0.5	31
99	Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clinical and Experimental Dermatology, 2006, 31, 520-524.	0.6	39
100	Aggressive CD30 Large Cell Lymphoma after Cyclosporine Given for Putative Atopic Dermatitis. Dermatology, 2006, 213, 239-241.	0.9	23
101	Basic immunosuppressive drugs outside solid organ transplantation. Expert Opinion on Investigational Drugs, 2006, 15, 267-291.	1.9	3
102	Risk of Myocardial Infarction in Patients With Psoriasis. JAMA - Journal of the American Medical Association, 2006, 296, 1735.	3.8	1,571
103	Therapy of cutaneous lupus erythematosus. Expert Review of Dermatology, 2006, 1, 105-120.	0.3	2
104	Methotrexateâ€“betamethasone weekly oral pulse in psoriasis. Journal of Dermatological Treatment, 2007, 18, 291-294.	1.1	17
105	Psoriasis in the elderly. Aging Health, 2007, 3, 611-623.	0.3	5
106	Advances in Immunosuppressive Therapy. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 398-417.	0.8	52
107	Childhood psoriasis. Clinics in Dermatology, 2007, 25, 555-562.	0.8	112
108	Amphiphilic Gels as a Potential Carrier for Topical Drug Delivery. Drug Delivery, 2007, 14, 75-85.	2.5	13
109	Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1004-1012.	0.7	29
110	Assessment of publications using methods of evidence-based medicine: an introduction using a dermatological clinical study. JDDG - Journal of the German Society of Dermatology, 2007, 5, 793-800.	0.4	2
111	Literaturbewertung mit Instrumenten der evidenzbasierten Medizin: eine EinfÃ¼hrung anhand einer dermatologischen Therapiestudie. JDDG - Journal of the German Society of Dermatology, 2007, 5, no-no.	0.4	0
112	The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Archives of Dermatological Research, 2008, 300, 545-550.	1.1	12
113	Role of photodynamic therapy in psoriasis: a brief review. Photodermatology Photoimmunology and Photomedicine, 2008, 24, 222-230.	0.7	35
114	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. New England Journal of Medicine, 2008, 358, 241-251.	13.9	366

#	ARTICLE	IF	CITATIONS
117	Treatment of Psoriasis. , 2008, , .		3
119	A Comparison of Mycophenolate Mofetil with Ciclosporine for the Treatment of Chronic Plaque-Type Psoriasis. <i>Dermatology</i> , 2009, 219, 126-132.	0.9	24
120	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 451-485.	0.6	505
121	Tumour necrosis factor- $\hat{\pm}$ blockers in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 1169-1171.	1.4	1
124	Immunomodulation in Dermatology. , 2010, , 29-38.		0
125	Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 838-853.	0.6	86
126	The use of cyclosporine in dermatology: Part II. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 949-972.	0.6	117
127	The use of cyclosporine in dermatology: Part I. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 925-946.	0.6	136
129	Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 537-545.	0.6	65
130	Childhood Psoriasis Treatment: Evidence Published Over the Last 5 Years. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 36-43.	0.4	15
131	Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity. <i>Current Pharmaceutical Design</i> , 2012, 18, 4526-4536.	0.9	3
132	Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. <i>British Journal of Dermatology</i> , 2012, 166, 811-818.	1.4	100
133	Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. <i>Journal of Dermatological Treatment</i> , 2012, 23, 290-304.	1.1	44
134	The Unique Impact of Psoriasis on the Geriatric Population: A Review. <i>Psoriasis Forum</i> , 2012, 18a, 15-21.	0.1	0
135	Does infection play a role in the pathogenesis of granuloma annulare?. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 342-343.	0.6	11
136	Maintenance treatment of psoriasis with cyclosporine A: Comparison between continuous and weekend therapy. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 341-342.	0.6	23
137	Ciclosporin Use During Pregnancy. <i>Drug Safety</i> , 2013, 36, 279-294.	1.4	109
138	Lifeâ€long diseases need lifeâ€long treatment: longâ€term safety of ciclosporin in canine atopic dermatitis. <i>Veterinary Record</i> , 2014, 174, 3-12.	0.2	39



#	ARTICLE	IF	CITATIONS
139	Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. <i>Journal of Dermatology</i> , 2014, 41, 974-980.	0.6	65
140	The role of medications and their management in acute kidney injury. <i>Integrated Pharmacy Research &amp; Practice</i> , 2015, 4, 21.	0.9	4
141	Cyclosporine. , 2016, , 63-73.		0
142	Current challenges and emerging drug delivery strategies for the treatment of psoriasis. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1461-1473.	2.4	31
143	Biologic treatments for elderly patients with psoriasis. <i>Journal of Dermatology</i> , 2017, 44, 1020-1023.	0.6	27
144	Cyclosporine in the Treatment of Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2017, 9, 98-101.	0.1	2
145	Systemic Therapies in Psoriasis. , 2018, , 145-158.		0
146	Oral Agents for Psoriasis. <i>Updates in Clinical Dermatology</i> , 2018, , 55-71.	0.1	0
148	A meta-analysis of cyclosporine treatment for Stevens&ndash;Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 135-142.	1.6	58
149	Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment. <i>Annals of Dermatology</i> , 2018, 30, 143.	0.3	15
150	Recent advances in cyclosporine drug delivery: challenges and opportunities. <i>Drug Delivery and Translational Research</i> , 2019, 9, 1067-1081.	3.0	46
151	British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. <i>British Journal of Dermatology</i> , 2019, 180, 1312-1338.	1.4	26
152	Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. <i>Dermatology and Therapy</i> , 2020, 10, 589-613.	1.4	49
153	Joint American Academy of Dermatology&quot;National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486.	0.6	184
154	Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma in a Patient Treated with Cyclosporine for Actinic Reticuloid. <i>Case Reports in Dermatological Medicine</i> , 2020, 2020, 1-5.	0.1	2
155	Cyclosporine. , 2021, , 187-198.e3.		4
156	Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 controlled trial. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 214-222.	0.2	8
159	Principles of Systemic Therapy. , 2010, , 63-76.		1

#	ARTICLE	IF	CITATIONS
160	Erythemato-Papulo-Squamous Diseases. , 2000, , 571-647.		9
162	Prolonged remission of psoriasis with azathioprine pulse therapy. Indian Journal of Dermatology, 2015, 60, 360.	0.1	7
163	Psoriasis Vulgaris and Arthropathica. , 2001, , 267-282.		0
164	Lessons for transplantation of cyclosporine experience in the treatment of autoimmune diseases. , 2001, , 201-213.		0
165	Neue immunmodulierende Strategien in der Dermatologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2001, , 67-74.	0.0	0
166	Drugs for the Treatment of Specific Skin Diseases. , 2005, , 325-344.		0
167	Traitement du psoriasis. , 2008, , 1199-1221.		0
169	Psoriasis Vulgaris and Arthropathica. , 2011, , 325-348.		0
170	Plaque psoriasis in children and adolescents &ndash; the role of etanercept. Psoriasis: Targets and Therapy, 0, , 25.	1.2	0
172	A Successful Treatment of Ostraceous Psoriasis Associated with Psoriatic Arthritis in Children: A Case Report. Psoriasis: Targets and Therapy, 2020, Volume 10, 61-66.	1.2	1
173	Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition#. International Journal of Dermatology and Venereology, 2020, 3, 14-26.	0.1	4
174	Traditional systemic therapy I: methotrexate and cyclosporine. , 2008, , 103-120.		3
177	The effects of oral cyclosporine in plaque-type psoriasis: the experience of Andreas Sygros Hospital. Therapy: Open Access in Clinical Medicine, 2004, 1, 217-221.	0.2	0
178	A practical approach to treating autoimmune bullous disorders with systemic medications. Journal of Clinical and Aesthetic Dermatology, 2009, 2, 19-28.	0.1	70
179	Modern treatment methods for patients with psoriasis. Vestnik Dermatologii I Venerologii, 2011, 87, 11-14.	0.2	1
180	Cyclic Immunosuppressive Drugs. , 0, , 275-292.		0
181	Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Dermato-Venereologica, 2006, 86, 184-185.	0.6	10
182	Treatment algorithms for special cases. Turkderm, 0, , 80-85.	0.0	0

#	ARTICLE	IF	CITATIONS
183	Cyclosporine. , 2013, , 199-211.e2.		4
184	Psoriasis and Atopic Dermatitis: Addressing Therapeutic Paradigms by Learning from Each Other. EMJ Dermatology, 0, , .	0.0	0